Potential of antisense therapy for facioscapulohumeral muscular dystrophy

Bibliography

• Upadhyaya M, Maynard J, Osborn M, et al. Germinal mosaicism in facioscapulohumeral muscular dystrophy (FSHD). Muscle & nerve Supplement 1995;2:S45-9
   Google Scholar
• Gabriels J, Beckers MC, Ding H, et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene 1999;236(1):25-32
   PubMed Web of Science ®Google Scholar
• Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010;329(5999):1650-3
   PubMed Web of Science ®Google Scholar
• Touznik A, Lee JJ, Yokota T. New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 2014;14(6):809-19
   PubMed Web of Science ®Google Scholar
• Lee J, Yokota T. Antisense Therapy in Neurology. J Personalized Med 2013;3(3):144-76
   PubMedGoogle Scholar
• Aoki Y, Nagata T, Yokota T, et al. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-alpha2 chain-null congenital muscular dystrophy mice. Human Mol Genet 2013;22(24):4914-28
   PubMed Web of Science ®Google Scholar
• Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, et al. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 2011;478(7367):127-31
   PubMed Web of Science ®Google Scholar
• Vanderplanck C, Ansseau E, Charron S, et al. The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One 2011;6(10):e26820
   PubMed Web of Science ®Google Scholar
• Pandey SN, Lee YC, Yokota T, Chen YW. Morpholino treatment improves muscle function and pathology of Pitx1 transgenic mice. Mol Ther 2014;22(2):390-6
   PubMed Web of Science ®Google Scholar
• Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle & Nerve 2006;34(1):1-15
   PubMed Web of Science ®Google Scholar
• Zatz M, Marie SK, Cerqueira A, et al. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am J Med Genet 1998;77(2):155-61
   PubMed Web of Science ®Google Scholar
• Gabellini D, D’Antona G, Moggio M, et al. Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 2006;439(7079):973-7
   PubMed Web of Science ®Google Scholar
• Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet Muscle 2014;4:12
   PubMed Web of Science ®Google Scholar
• Krom YD, Thijssen PE, Young JM, et al. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. Plos Genet 2013;9(4):e1003415
   PubMed Web of Science ®Google Scholar
• Snider L, Geng LN, Lemmers RJ, et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. Plos Genet 2010;6(10):e1001181
   PubMed Web of Science ®Google Scholar
• Hewitt JE, Lyle R, Clark LN, et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet 1994;3(8):1287-95
   PubMed Web of Science ®Google Scholar
• Snider L, Asawachaicharn A, Tyler AE, et al. RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet 2009;18(13):2414-30
   PubMed Web of Science ®Google Scholar
• Dixit M, Ansseau E, Tassin A, et al. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci USA 2007;104(46):18157-62
   PubMed Web of Science ®Google Scholar
• de Greef JC, Wohlgemuth M, Chan OA, et al. Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD. Neurology 2007;69(10):1018-26
   PubMed Web of Science ®Google Scholar
• Hartweck LM, Anderson LJ, Lemmers RJ, et al. A focal domain of extreme demethylation within D4Z4 in FSHD2. Neurology 2013;80(4):392-9
   PubMed Web of Science ®Google Scholar
• Tassin A, Laoudj-Chenivesse D, Vanderplanck C, et al. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy? J Cell Mol Med 2013;17(1):76-89
   PubMed Web of Science ®Google Scholar
• Pandey SN, Cabotage J, Shi R, et al. Conditional over-expression of PITX1 causes skeletal muscle dystrophy in mice. Biol Open 2012;1(7):629-39
   PubMed Web of Science ®Google Scholar
• Bosnakovski D, Xu Z, Gang EJ, et al. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO journal 2008;27(20):2766-79
   PubMed Web of Science ®Google Scholar
• Kowaljow V, Marcowycz A, Ansseau E, et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord 2007;17(8):611-23
   PubMed Web of Science ®Google Scholar
• Wallace LM, Garwick SE, Mei W, et al. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann Neurol 2011;69(3):540-52
   PubMed Web of Science ®Google Scholar
• Statland J, Tawil R. Facioscapulohumeral muscular dystrophy. Neurologic Clin 2014;32(3):721-8, ix
   PubMed Web of Science ®Google Scholar
• Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nature Genet 2012;44(12):1370-4
   PubMed Web of Science ®Google Scholar
• Wuebbles RD, Long SW, Hanel ML, Jones PL. Testing the effects of FSHD candidate gene expression in vertebrate muscle development. Int J Clin Exp Pathol 2010;3(4):386-400
   PubMed Web of Science ®Google Scholar
• Sarfarazi M, Wijmenga C, Upadhyaya M, et al. Regional mapping of facioscapulohumeral muscular dystrophy gene on 4q35: combined analysis of an international consortium. Am J Hum Genet 1992;51(2):396-403
   PubMed Web of Science ®Google Scholar
• Lemmers RJ, de Kievit P, Sandkuijl L, et al. Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat Genet 2002;32(2):235-6
   PubMed Web of Science ®Google Scholar
• Lemmers RJ, Wohlgemuth M, Frants RR, et al. Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy. Am J Hum Genet 2004;75(6):1124-30
   PubMed Web of Science ®Google Scholar
• van Deutekom JC, Wijmenga C, van Tienhoven EA, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 1993;2(12):2037-42
   PubMed Web of Science ®Google Scholar
• Wijmenga C, Hewitt JE, Sandkuijl LA, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 1992;2(1):26-30
   PubMed Web of Science ®Google Scholar
• Winokur ST, Bengtsson U, Feddersen J, et al. The DNA rearrangement associated with facioscapulohumeral muscular dystrophy involves a heterochromatin-associated repetitive element: implications for a role of chromatin structure in the pathogenesis of the disease. Chromosome Res 1994;2(3):225-34
   PubMed Web of Science ®Google Scholar
• van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 2003;35(4):315-17
   PubMed Web of Science ®Google Scholar
• Bosnakovski D, Choi SH, Strasser JM, et al. High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity. Skelet Muscle 2014;4(1):4
   PubMed Web of Science ®Google Scholar
• Rival-Gervier S, Lo MY, Khattak S, et al. Kinetics and epigenetics of retroviral silencing in mouse embryonic stem cells defined by deletion of the D4Z4 element. Mol Ther 2013;21(8):1536-50
   PubMed Web of Science ®Google Scholar
• Wallace LM, Liu J, Domire JS, et al. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. Mol Ther 2012;20(7):1417-23
   PubMed Web of Science ®Google Scholar
• McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008;105(15):5868-73
   PubMed Web of Science ®Google Scholar
• Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441(7092):537-41
   PubMed Web of Science ®Google Scholar
• Benato F, Skobo T, Gioacchini G, et al. Ambra1 knockdown in zebrafish leads to incomplete development due to severe defects in organogenesis. Autophagy 2013;9(4):476-95
   PubMed Web of Science ®Google Scholar
• Nagamine K, Matsuda A, Asashima M, Hori T. XRASGRP2 expression during early development of Xenopus embryos. Biochem Biophys Res Commun 2008;372(4):886-91
   PubMed Web of Science ®Google Scholar
• Reissner KJ, Sartor GC, Vazey EM, et al. Use of vivo-morpholinos for control of protein expression in the adult rat brain. J Neurosci Methods 2012;203(2):354-60
   PubMed Web of Science ®Google Scholar
• Satou Y, Imai KS, Satoh N. Action of morpholinos in Ciona embryos. Genesis 2001;30(3):103-6
   PubMed Web of Science ®Google Scholar
• Takeshima Y, Nishio H, Sakamoto H, et al. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Invest 1995;95(2):515-20
   PubMed Web of Science ®Google Scholar
• Wilton SD, Lloyd F, Carville K, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999;9(5):330-8
   PubMed Web of Science ®Google Scholar
• Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001;98(1):42-7
   PubMed Web of Science ®Google Scholar
• Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, et al. Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 2004;10(2):232-40
   PubMed Web of Science ®Google Scholar
• Saito T, Nakamura A, Aoki Y, et al. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS ONE 2010;5(8):e12239
   PubMed Web of Science ®Google Scholar
• Yokota T, Hoffman E, Takeda S. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. Methods Mol Biol 2011;709:299-312
   PubMedGoogle Scholar
• Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014;13(10):987-96
   PubMed Web of Science ®Google Scholar
• Echigoya Y, Aoki Y, Miskew B, et al. Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucliec Acids 2015;4:e225
   Google Scholar
• Betts CA, Saleh AF, Carr CA, et al. Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Scientific reports 2015;5:8986
   PubMed Web of Science ®Google Scholar
• Flanigan KM, Voit T, Rosales XQ, et al. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Neuromuscul Disord 2014;24(1):16-24
   PubMed Web of Science ®Google Scholar
• Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med 2011;364(16):1513-22
   PubMed Web of Science ®Google Scholar
• Heald AE, Iversen PL, Saoud JB, et al. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob agents Chemother 2014;58(11):6639-47
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Warren TK, et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob agents Chemother 2009;53(5):2089-99
   PubMed Web of Science ®Google Scholar
• Ma W, Lin Y, Xuan W, et al. Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs. Oncogene 2012;31(8):1024-33
   PubMed Web of Science ®Google Scholar
• Buller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015;372(3):232-40
   PubMed Web of Science ®Google Scholar
• Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997;7(3):187-95
   PubMedGoogle Scholar
• Hudziak RM, Barofsky E, Barofsky DF, et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 1996;6(4):267-72
   PubMedGoogle Scholar
• Summerton J, Stein D, Huang SB, et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 1997;7(2):63-70
   PubMedGoogle Scholar
• Taylor MF, Paulauskis JD, Weller DD, Kobzik L. In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA. J Biol Chem 1996;271(29):17445-52
   PubMed Web of Science ®Google Scholar
• Eisen JS, Smith JC. Controlling morpholino experiments: don’t stop making antisense. Development 2008;135(10):1735-43
   PubMed Web of Science ®Google Scholar
• Yokota T, Duddy W, Partridge T. Optimizing exon skipping therapies for DMD. Acta Myologica 2007;26(3):179-84
   PubMedGoogle Scholar
• Vitiello L, Bassi N, Campagnolo P, et al. In vivo delivery of naked antisense oligos in aged mdx mice: analysis of dystrophin restoration in skeletal and cardiac muscle. Neuromuscul Disord 2008;18(8):597-605
   PubMed Web of Science ®Google Scholar
• Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009;65(6):667-76
   PubMed Web of Science ®Google Scholar
• Malerba A, Thorogood FC, Dickson G, Graham IR. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 2009;20(9):955-65
   PubMed Web of Science ®Google Scholar
• Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta BBABiomembr 2010;1798(12):2296-303
   PubMed Web of Science ®Google Scholar
• Lehto T, Castillo Alvarez A, Gauck S, et al. Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res 2014;42(5):3207-17
   PubMed Web of Science ®Google Scholar
• Wu B, Li Y, Morcos PA, et al. Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 2009;17(5):864-71
   PubMed Web of Science ®Google Scholar
• Aoki Y, Yokota T, Nagata T, et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 2012;109(34):13763-8
   PubMed Web of Science ®Google Scholar
• Yokota T, Nakamura A, Nagata T, et al. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acids Ther 2012;22(5):306-15
   PubMed Web of Science ®Google Scholar
• Widrick JJ, Jiang S, Choi SJ, et al. An octaguanidine-morpholino oligo conjugate improves muscle function of mdx mice. Muscle Nerve 2011;44(4):563-70
   PubMed Web of Science ®Google Scholar
• Morcos PA, Li Y, Jiang S. Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques 2008;45(6):613-14
   PubMed Web of Science ®Google Scholar
• Moulton HM, Fletcher S, Neuman BW, et al. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans 2007;35(Pt 4):826-8
   PubMed Web of Science ®Google Scholar
• Jearawiriyapaisarn N, Moulton HM, Buckley B, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008;16(9):1624-9
   PubMed Web of Science ®Google Scholar
• Wu B, Moulton HM, Iversen PL, et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008;105(39):14814-19
   PubMed Web of Science ®Google Scholar
• Moulton HM, Wu B, Jearawiriyapaisarn N, et al. Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy. Ann N Y Acad Sci 2009;1175:55-60
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Babbs A, Powell D, et al. Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 2010;18(1):198-205
   PubMed Web of Science ®Google Scholar
• Jearawiriyapaisarn N, Moulton HM, Sazani P, et al. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 2010;85(3):444-53
   PubMed Web of Science ®Google Scholar
• Crisp A, Yin H, Goyenvalle A, et al. Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet 2011;20(3):413-21
   PubMed Web of Science ®Google Scholar
• Wu B, Cloer C, Lu P, et al. Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice. Gene Ther 2014;21(9):785-93
   PubMed Web of Science ®Google Scholar
• Yin H, Moulton HM, Betts C, et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009;18(22):4405-14
   PubMed Web of Science ®Google Scholar
• Betts C, Saleh AF, Arzumanov AA, et al. Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucliec Acids 2012;1:e38
   Google Scholar
• Yin H, Saleh AF, Betts C, et al. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 2011;19(7):1295-303
   PubMed Web of Science ®Google Scholar
• Yin H, Moulton HM, Seow Y, et al. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 2008;17(24):3909-18
   PubMed Web of Science ®Google Scholar
• Hoffman E. A rebirth for drisapersen in Duchenne muscular dystrophy? Lancet neurology 2014;13(10):963-5
   PubMed Web of Science ®Google Scholar
• Lu QL, Cirak S, Partridge T. What can we learn from clinical trials of exon skipping for DMD? Mol Ther Nucliec Acids 2014;3:e152
   Google Scholar
• Lee JJ, Yokota T. Antisense therapy in neurology. J Pers Med 2013;3(3):144-76
   PubMedGoogle Scholar
• Wirth B, Barkats M, Martinat C, et al. Moving towards treatments for spinal muscular atrophy: hopes and limits. Exp Opin Emerg Drugs 2015;1-4
   PubMed Web of Science ®Google Scholar
• Kaczmarek A, Schneider S, Wirth B, Riessland M. Investigational therapies for the treatment of spinal muscular atrophy. Exp Opin Invest Drugs 2015;1:15
   Google Scholar
• Mitrpant C, Porensky P, Zhou H, et al. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS ONE 2013;8(4):e62114
   PubMed Web of Science ®Google Scholar
• Zhou H, Janghra N, Mitrpant C, et al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther 2013;24(3):331-42
   PubMed Web of Science ®Google Scholar
• Rigo F, Hua Y, Krainer AR, Bennett CF. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol 2012;199(1):21-5
   PubMed Web of Science ®Google Scholar
• Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011;478(7367):123-6
   PubMed Web of Science ®Google Scholar
• Hoffman EP, Bronson A, Levin AA, et al. Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol 2011;179(1):12-22
   PubMed Web of Science ®Google Scholar
• Ferguson DP, Dangott LJ, Lightfoot JT. Lessons learned from vivo-morpholinos: How to avoid vivo-morpholino toxicity. Biotechniques 2014;56(5):251-6
   PubMed Web of Science ®Google Scholar
• Leidenroth A, Clapp J, Mitchell LM, et al. Evolution of DUX gene macrosatellites in placental mammals. Chromosoma 2012;121(5):489-97
   PubMed Web of Science ®Google Scholar